REGISTER
First New ADHD Drug Approved in China
AK0901, a combination capsule containing dexmethylphenidate and serdexmethylphenidate, has been approved in China for ADHD in patients aged 6 years and older. The product offers rapid onset plus all-day control and is positioned as the first such option in the Chinese market.

On January 5, the National Medical Products Administration (NMPA) website showed that YS Biopharma’s serdexmethylphenidate/dexmethylphenidate combination capsules (development code: AK0901; brand name: Aizhida) were approved for marketing. In April 2025, the drug was granted priority review by the Center for Drug Evaluation (CDE) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in patients aged 6 years and older.

AK0901 is the world’s first and currently only combination product containing immediate-release dexmethylphenidate (d-MPH) and the prodrug serdexmethylphenidate (SDX). It is a best-in-class innovative therapy for patients with ADHD. The drug acts on dopamine and norepinephrine reuptake in the brain, increasing synaptic concentrations and improving neurotransmission efficiency, thereby alleviating ADHD symptoms.

AK0901 was approved in the United States in March 2021 under the overseas brand name Azstarys. It was the first methylphenidate product approved by the FDA in nearly 20 years, and its immediate-release plus extended-release combination design brought comprehensive improvements in clinical efficacy, safety, and tolerability.

Compared with single-agent extended-release formulations, the unique biphasic-release pharmacokinetic profile of AK0901 better matches the all-day needs of patients with ADHD, from getting up in the morning through daytime work, study and social activity to evening homework or work and sleep. It is suitable not only for school-age children and adolescents aged 6 years and older, but also for adults with ADHD, while reducing adherence problems and sleep disruption associated with multiple daily doses.

In December 2021, YS Biopharma entered into a licensing collaboration worth a total of US$105.5 million with Commave Therapeutics, obtaining the rights to develop, manufacture, and commercialize AK0901 in Greater China.

In March 2025, YS Biopharma announced the successful completion of a Phase III trial of AK0901 for ADHD in China. The study was jointly led by Beijing Anding Hospital, Capital Medical University and Peking University Sixth Hospital across eight clinical trial centers nationwide, and evaluated the efficacy, safety, and tolerability of oral AK0901 in children aged 6–12 years with ADHD.

The study met both the primary endpoint and the key secondary endpoint, with statistically significant and clinically meaningful improvements versus placebo at all visits.

In China, the prevalence of ADHD among children and adolescents is 6.4%, corresponding to more than 23 million patients, yet therapeutic options remain limited. Methylphenidate has long been recommended in domestic and international guidelines as a first-line therapy for children and adults with ADHD, and has been the most widely used medicine in clinical practice since its launch in 2000. As a third-generation methylphenidate product, AK0901 directly addresses clinical pain points through its innovative combination design. Its approval makes it the first ADHD therapy in China to combine rapid onset with long-duration control, filling a clinical gap and offering patients a preferred treatment option.

0
0
Loading